We updated the design of this site on September 25th. Learn more.

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00394472

First Posted: November 1, 2006

Last Update Posted: March 18, 2013

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

AstraZeneca

Purpose

The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.

Condition	Intervention	Phase
Gastroesophageal Reflux Disease (GERD)	Drug: AZD3355	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment
Official Title:	A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.

Resource links provided by NLM:

MedlinePlus related topics: GERD

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of Material Upwards From the Stomach' During the Last Seven Days of Treatment [ Time Frame: Twice daily during the last seven days on treatment ]
Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Disease Questionnaire (RDQ) diary

Secondary Outcome Measures:

Plasma Concentration (µmol/L) of AZD3355 Analysed From Blood Sample Taken in the Interval One to Two Hours After the First Intake of AZD3355 65 mg Capsule [ Time Frame: An interval of one to two hours after the first intake of AZD3355 65 mg capsule ]


Enrollment:	244
Study Start Date:	November 2006
Study Completion Date:	June 2007
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Intervention Details:

Other Name: Lesogaberan

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	17 Years to 70 Years (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provision of written informed consent
At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms
Continuous treatment with Proton Pump Inhibitor (PPI)
Ability to read and write

Exclusion Criteria:

Prior surgery of the upper gastrointestinal (GI) tract
History of clinically significant diseases other than GERD
Need for concomitant medication with drugs that may influence gastrointestinal symptoms

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00394472

Show 38 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Göran Hasselgren, MD	AstraZeneca
Principal Investigator:	Guy Boeckxstaens, MD	Academisch Medisch Centrum Universiteit van Amsterdam

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M, Denison H. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut. 2011 Sep;60(9):1182-8. doi: 10.1136/gut.2010.235630. Epub 2011 Mar 14.


Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00394472 History of Changes
Other Study ID Numbers:	D9120C00011 EUDRACT No 2006-003541-16
First Submitted:	October 31, 2006
First Posted:	November 1, 2006
Results First Submitted:	August 11, 2011
Results First Posted:	March 18, 2013
Last Update Posted:	March 18, 2013
Last Verified:	February 2013

Keywords provided by AstraZeneca:


Heartburn Patient reported symptoms Proton pump inhibitor

Additional relevant MeSH terms:


Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Proton Pump Inhibitors Lesogaberan	Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents GABA-A Receptor Agonists GABA Agonists GABA Agents Neurotransmitter Agents Physiological Effects of Drugs

To Top